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The data on the fourth row of the table, labelled
“Morning PEF (l/min): difference in LS mean change from
baseline (95% CI) over weeks 1e24”, should read as follows:
 FF100 mg OD vs. placebo: 12.1 (4.0, 20.2)DOI of original article: http://dx.doi.org/10.1016/
j.rmed.2013.11.009.
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creativecommons.org/licenses/by-nc-nd/3.0/). FP250 mg BD vs. placebo: 7.6 (0.5, 15.7)
This amendment does not materially affect the findings
or interpretations presented in the manuscript.
The authors would like to apologise for any inconve-
nience caused.an open access article under the CC BY-NC-ND license (http://
